Overview

Webcast ImageWebcast - Replay
Aptose to Present New APTO-253 Data at the 2016 ASH Annual Meeting
December 3, 2016 at 5:30 p.m. PT
Aptose to Present New APTO-253 Data at the 2016 ASH Annual Meeting
Saturday, December 3, 2016 5:30 p.m. PT  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar

Corporate Profile

Aptose Biosciences is a clinical-stage biotechnology company developing personalized therapies to address unmet medical needs in oncology, with a particular focus on hematologic malignancies. Aptose is advancing new therapeutics focused on well validated and novel drug targets on the leading edge of cancer research, coupled with validated biomarkers to identify the optimal patient population for our products. The company's small molecule cancer therapeutics pipeline includes products designed for potent single agent activity and to enhance the efficacy of existing anti-cancer therapies without overlapping toxicities. Aptose Biosciences Inc. is listed on NASDAQ under the symbol APTO and on the TSX under the symbol APS.

Stay Connected

Receive Email Alerts
Sign up to receive email alerts whenever Aptose Biosciences, Inc. posts new information to the site. Just enter your email address and click Submit.
 

Contact Information

Investor Relations
647-479-9825
ir@aptose.com

Data provided by Nasdaq. Minimum 15 minutes delayed.